Oversight Mechanisms for Clinical Research-Reference-Cited by-同舟云学术

Oversight Mechanisms for Clinical Research

Published:2000-01-28 Issue:5453 Volume:287 Page:595-597
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Snyderman Ralph¹,Holmes Edward W.²

Affiliation:

1. R. Snyderman is the Chancellor for Health Affairs, Duke University, President/CEO, Duke University Health System, DUMC 3701, Durham, NC 27710, USA.

2. E. Holmes is Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs, Duke University Medical Center, Durham, NC 27710, USA.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference8 articles.

1. Varmus H., Satcher D., N. Engl. J. Med.337, 1003 (1997).

2. Kass N. E., Sugarman J., Kennedy Inst. Ethics J.6, 271 (1996).

3. “Drug trials hide conflicts for doctors,”;Eichenwald K.;New York Times,1999

4. “Dying for a cure,”;Kaplan S.;U.S. News & World Report,1999

5. Snyderman R., “For the health of the public: Ensuring the future of clinical research,”Report of the AAMC Task Force on Clinical Research, (Association of American Medical Colleges, Washington, DC, 2000), vol. I.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Dysregulation of Human Subjects Research;JAMA;2007-11-14

2. Systematic identification and classification of adverse events in human research;Contemporary Clinical Trials;2006-06

3. Informed Consent and the Elusive Dichotomy Between Standard and Experimental Therapy;American Journal of Law & Medicine;2002-12

4. Lessons Learned From Recent Cardiovascular Clinical Trials: Part II;Circulation;2002-08-13

5. IRB Reform;New England Journal of Medicine;2002-05-02